This, below, is a bit old but could be the jab defenders' counterargument, unless things have changed. I'm not saying I agree with it. However it was reported that at an average 53 days after diagnosis approximately 60% of the jabbed who had had covid had no detectable antibodies against the nucleocapsid protein v approximately 7% of unj…
This, below, is a bit old but could be the jab defenders' counterargument, unless things have changed. I'm not saying I agree with it. However it was reported that at an average 53 days after diagnosis approximately 60% of the jabbed who had had covid had no detectable antibodies against the nucleocapsid protein v approximately 7% of unjabbed.
Clinical Trials Update, August 23/30, 2022
Antibody Testing’s Limits for Detecting Prior SARS-CoV-2 Infection, Anita Slomski
JAMA. 2022;328(8):700-701. doi:10.1001/jama.2022.14324, COVID-19 Resource Center
"Serology tests that detect antibodies to the SARS-CoV-2 nucleocapsid protein have played a key role in tracking infections in clinical trials and at population levels because they reveal prior rather than acute infection. But currently used messenger RNA (mRNA) vaccines elicit antibodies to the novel coronavirus’ spike protein rather than the nucleocapsid protein, raising questions about how tests that measure nonspike antibodies will perform in areas with high vaccination coverage.
To find out, investigators carried out a substudy of 30 420 US adults enrolled in the mRNA-1273 (Moderna) phase 3 trial conducted in 2020. Participants had been randomly assigned to receive 2 doses of mRNA-1273 vaccine or placebo given on days 1 and 29. Serology testing was conducted on days 1, 29, and 57 and at the decision visit when participants were offered mRNA-1273 vaccination if they were previously assigned to a placebo group.
The investigators reported in the Annals of Internal Medicine that among 700 trial participants who had COVID-19 confirmed by polymerase chain reaction during the trial’s blinded, placebo-controlled phase, about 40% of the vaccinated group compared with approximately 93% of those who received placebo had detectable antibodies against the nucleocapsid protein (anti-N Abs) at an average 53 days after diagnosis. Viral load was a factor: each 1-log increase in SARS-CoV-2 viral copies at diagnosis nearly doubled the odds of anti-N Ab seroconversion.
“[T]hese data suggest that assay limitations may exist in detecting anti-N Abs in persons recently vaccinated with mRNA-1273,” the authors wrote, noting that clinicians should consider an individual’s vaccination history when they determine seropositivity based on anti-N Ab testing."
This, below, is a bit old but could be the jab defenders' counterargument, unless things have changed. I'm not saying I agree with it. However it was reported that at an average 53 days after diagnosis approximately 60% of the jabbed who had had covid had no detectable antibodies against the nucleocapsid protein v approximately 7% of unjabbed.
Clinical Trials Update, August 23/30, 2022
Antibody Testing’s Limits for Detecting Prior SARS-CoV-2 Infection, Anita Slomski
JAMA. 2022;328(8):700-701. doi:10.1001/jama.2022.14324, COVID-19 Resource Center
"Serology tests that detect antibodies to the SARS-CoV-2 nucleocapsid protein have played a key role in tracking infections in clinical trials and at population levels because they reveal prior rather than acute infection. But currently used messenger RNA (mRNA) vaccines elicit antibodies to the novel coronavirus’ spike protein rather than the nucleocapsid protein, raising questions about how tests that measure nonspike antibodies will perform in areas with high vaccination coverage.
To find out, investigators carried out a substudy of 30 420 US adults enrolled in the mRNA-1273 (Moderna) phase 3 trial conducted in 2020. Participants had been randomly assigned to receive 2 doses of mRNA-1273 vaccine or placebo given on days 1 and 29. Serology testing was conducted on days 1, 29, and 57 and at the decision visit when participants were offered mRNA-1273 vaccination if they were previously assigned to a placebo group.
The investigators reported in the Annals of Internal Medicine that among 700 trial participants who had COVID-19 confirmed by polymerase chain reaction during the trial’s blinded, placebo-controlled phase, about 40% of the vaccinated group compared with approximately 93% of those who received placebo had detectable antibodies against the nucleocapsid protein (anti-N Abs) at an average 53 days after diagnosis. Viral load was a factor: each 1-log increase in SARS-CoV-2 viral copies at diagnosis nearly doubled the odds of anti-N Ab seroconversion.
“[T]hese data suggest that assay limitations may exist in detecting anti-N Abs in persons recently vaccinated with mRNA-1273,” the authors wrote, noting that clinicians should consider an individual’s vaccination history when they determine seropositivity based on anti-N Ab testing."
https://jamanetwork.com/journals/jama/fullarticle/2795530